When it comes to cancer, everyone is very worried. The incidence and mortality of cancer worldwide are rising. According to statistics [1], the global cancer
Colorectal cancer (CRC) is one of the most common malignant tumors, and its prevalence ranks third among malignant tumors. Despite the success of new targeted
On September 21, 2022, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has accelerated approval of its precision oncology drug Retevmo (selpercatinib,
According to a recent GLOBOCAN, colorectal cancer (CRC) has the third highest incidence of all cancers and the second highest mortality rate in 2020, according
The Birth of ADC Drugs In today’s anti-tumor treatment, many chemotherapeutic drugs have been found to have a killing effect on tumor cells. Unfortunately, chemotherapeutic
ADC Drug Assessment Background Before designing a DDI assessment strategy for a drug, an understanding of the properties of the drug itself is required. Therefore,
The immune system has evolved to protect the body from a variety of potential threats. These threats include bacterial diseases, such as plague, cholera, diphtheria,
The rise of immunotherapy has greatly improved the treatment pattern of advanced lung cancer and provided more possibilities for personalized diagnosis and treatment of tumors.
Cell-based immunotherapy — CAR-T cell therapy — has revolutionized the treatment of several cancers. The therapy uses genetically engineered T cells to target and attack
Targeted drugs are the most eye-catching progress in lung cancer treatment in recent years, which have significantly improved the prognosis of patients with advanced lung
An ADC consists of three basic elements: a tumor-specific monoclonal antibody (mAb), a small cytotoxic molecule called a payload, and a linker (Linker) that connects
Targeted therapy is to design a corresponding therapeutic drug at the cellular and molecular level, targeting a well-defined carcinogenic site (the site can be a
